Click here to close now.

Welcome!

Microsoft Cloud Authors: Liz McMillan, Elizabeth White, Pat Romanski, Jaynesh Shah, Carmen Gonzalez

News Feed Item

Eventide Asset Management Launches the Eventide Healthcare & Life Sciences Fund

BOSTON, MA -- (Marketwire) -- 01/11/13 -- Eventide Asset Management, LLC, a Boston-based investment advisory firm that is committed to biblically responsible investing, has launched the Eventide Healthcare & Life Sciences Fund (NASDAQ: ETGLX) on December 27, 2012. The Eventide Healthcare & Life Sciences Fund is a non-diversified fund that uses bottom-up fundamental research to find healthcare and life sciences companies with the potential to appreciate in value as positive data is released regarding clinical trials and FDA feedback, and market acceptance of products. The Fund has four share classes: ETNHX (N), ETIHX, (I), ETAHX (A), and ETCHX (C).

Healthcare and life sciences companies include those companies that derive or are expected to derive 50% or more of their revenue from healthcare and life science products and services including, but not limited to, biotechnology, pharmaceuticals, diagnostics, life science tools, medical devices, healthcare information technology, healthcare services, synthetic biology, agricultural and environmental management, and pharmaceutical manufacturing products and services. These companies include smaller development-stage companies.

According to lead portfolio manager Finny Kuruvilla, MD PhD, despite revolutionary advances in biology, we've only witnessed its nascency. Dr. Kuruvilla commented: "There is what I call an 'opportunity vacuum' for health and life sciences, as scientific understanding significantly outpaces approved treatments it the marketplace. This highly addressable pipeline, combined with the deepening pockets and growing appetites of large biopharma, promise exciting investment opportunities well into the future." In support of this investment thesis, Kuruvilla cited a recent report from Morgan Stanley and Thomson Reuters indicating a widening gap between the free cash flow of large biopharma companies and the entire US smid-cap biotech market capitalization. In other words, "Large biopharma has more money to spend than there are opportunities to buy, and the gap is widening, not closing," said Kuruvilla.

In addition to a compelling investment thesis, investors should be attracted to the Eventide Healthcare & Life Sciences Fund because of the expectation of diversification benefits in broad investment portfolios. According to the Morgan Stanley Strategy team, biotechnology has the most non-correlation of any industry group. This is especially true of small-cap biotechnology companies, where risks are typically more tied to company-specific events -- such as, clinical trial data releases and FDA feedback -- than to macro-economic forces.

The Eventide Healthcare & Life Sciences Fund will be managed by Eventide's lead portfolio manager, Finny Kuruvilla, MD PhD. Dr. Kuruvilla has been primarily responsible for the day-to-day management of the Eventide Gilead Fund since its inception on July 8, 2008. The Eventide Gilead Fund is a diversified mutual fund that primarily invests in small and mid-cap growth companies. Under his leadership, the Eventide Gilead Fund's no-load class (NASDAQ: ETGLX) has returned an annualized performance of 11.08% from July 8, 2008 to December 31, 2012 net of all fees, while the S&P 500 has returned 4.88% and the Russell Midcap Growth Index 6.00%. The fund has garnered numerous awards from the Wall Street Journal for its outperformance since inception in July 2008.

Along with his role as portfolio manager at Eventide, Dr. Kuruvilla also serves as Principal at Clarus Ventures, a health care venture capital firm with $1.2 billion under management. He represents Clarus on the Board of Directors of Nanostring, and is also a Board Observer for Catabasis, Lycera, Tetralogic, and Virdante. He has cared for adult and pediatric patients suffering from a wide variety of hematologic, oncologic, and autoimmune disorders at the Brigham & Women's Hospital, Children's Hospital Boston, the Dana Farber Cancer Institute, the Beth Israel Deaconess Hospital, and the Massachusetts General Hospital. He has also conducted research at the Broad Institute of Harvard and MIT in medical genetics from 2006 to 2008. Dr. Kuruvilla did his residency at the Brigham & Women's Hospital from 2003 to 2006 and his fellowship in transfusion medicine at Harvard Medical School from 2006 to 2007. He received his MD from Harvard Medical School, his PhD in chemistry and chemical biology from Harvard University, his master's degree in electrical engineering and computer science from MIT, and his bachelor's degree from Caltech.

The following table shows the Gilead Fund's performance since inception:

----------------------------------------------------------------------------
                                                                   Since
                                                      3 year     inception
 As of 12/31/2012              YTD return  1 year   annualized  (7/08/2008)
                                           return     return     annualized
                                                                   return
----------------------------------------------------------------------------
Eventide Gilead Fund*            18.15%    18.15%     11.95%       11.08%
----------------------------------------------------------------------------
S&P 500 Total Return Index       16.00%    16.00%     10.87%       4.88%
----------------------------------------------------------------------------
Russell Mid-Cap Growth Total
Return Index                     15.81%    15.81%     12.91%       6.00%
----------------------------------------------------------------------------

Eventide Gilead Fund expenses ratios: Gross Expenses 2.05%; Net Expenses 1.64%. The advisor has agreed to maintain the Fund's total annual operating expenses at 1.64% until at least October 31, 2013. Three-year and inception returns are annualized. The performance data quoted here represents past performance. Current performance may be lower or higher than the performance data quoted above. Past performance is no guarantee of future results. The investment return and principal value of an investment will fluctuate so that investor's shares, when redeemed, may be worth more or less than their original cost. Please review the fund's prospectus for more information regarding the fund's fees and expenses. Performance shown is for No-load Class shares (please see a prospectus for information about other share classes). For performance information current to the most recent month-end, please call toll-free 877-771-EVEN (3836).

The S&P 500 is an index created by Standard & Poor's Corp considered to represent the performance of the stock market generally. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. It includes mid-cap companies with higher price-to-book ratios and forecasted growth. Neither index is an investment product available for purchase.

Mutual Funds involve risk including the possible loss of principal. Both the Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and they normally have a lower trading volume than larger companies. The Funds' ethical values screening criteria could cause it to underperform similar funds that do not have such screening criteria. The Eventide Healthcare & Life Sciences fund is non-diversified and its performance largely depends on the overall condition of the healthcare sector. The Eventide Gilead Fund and Eventide Healthcare & Life Sciences Fund can both have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. The funds can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The fund can have risk associated with a higher portfolio turnover which could result in higher transactional costs.

An investor should consider the Fund's investment objectives, risks, charges and expenses carefully before investing or sending money. This and other important information about the Eventide Gilead Fund can be found in the Fund's prospectus. Please read the prospectus carefully before investing. To obtain a current prospectus please call the fund, toll free at 877-771- EVEN (3836). You can also obtain a prospectus at www.eventidefunds.com. The Eventide Gilead Fund is distributed by Northern Lights Distributors, LLC, which is not affiliated with Eventide Asset Management, LLC.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Fund Contact:
Robin John
877-771-EVEN (3836), x55

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

@ThingsExpo Stories
SYS-CON Events announced today that BMC will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. BMC delivers software solutions that help IT transform digital enterprises for the ultimate competitive business advantage. BMC has worked with thousands of leading companies to create and deliver powerful IT management services. From mainframe to cloud to mobile, BMC pairs high-speed digital innovation with robust IT industrialization – allowing customers to provide amazing user experiences with optimized IT per...
SYS-CON Events announced today that MetraTech, now part of Ericsson, has been named “Silver Sponsor” of SYS-CON's 16th International Cloud Expo®, which will take place on June 9–11, 2015, at the Javits Center in New York, NY. Ericsson is the driving force behind the Networked Society- a world leader in communications infrastructure, software and services. Some 40% of the world’s mobile traffic runs through networks Ericsson has supplied, serving more than 2.5 billion subscribers.
The world is at a tipping point where the technology, the device and global adoption are converging to such a point that we will see an explosion of a world where smartphone devices not only allow us to talk to each other, but allow for communication between everything – serving as a central hub from which we control our world – MediaTek is at the heart of both driving this and allowing the markets to drive this reality forward themselves. The next wave of consumer gadgets is here – smart, connected, and small. If your ambitions are big, so are ours. In his session at @ThingsExpo, Jack Hu, D...
SYS-CON Events announced today that DragonGlass, an enterprise search platform, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. After eleven years of designing and building custom applications, OpenCrowd has launched DragonGlass, a cloud-based platform that enables the development of search-based applications. These are a new breed of applications that utilize a search index as their backbone for data retrieval. They can easily adapt to new data sets and provide access to both structured and unstruc...
The 4th International Internet of @ThingsExpo, co-located with the 17th International Cloud Expo - to be held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA - announces that its Call for Papers is open. The Internet of Things (IoT) is the biggest idea since the creation of the Worldwide Web more than 20 years ago.
We’re entering a new era of computing technology that many are calling the Internet of Things (IoT). Machine to machine, machine to infrastructure, machine to environment, the Internet of Everything, the Internet of Intelligent Things, intelligent systems – call it what you want, but it’s happening, and its potential is huge. IoT is comprised of smart machines interacting and communicating with other machines, objects, environments and infrastructures. As a result, huge volumes of data are being generated, and that data is being processed into useful actions that can “command and control” thi...
As the Internet of Things unfolds, mobile and wearable devices are blurring the line between physical and digital, integrating ever more closely with our interests, our routines, our daily lives. Contextual computing and smart, sensor-equipped spaces bring the potential to walk through a world that recognizes us and responds accordingly. We become continuous transmitters and receivers of data. In his session at @ThingsExpo, Andrew Bolwell, Director of Innovation for HP's Printing and Personal Systems Group, discussed how key attributes of mobile technology – touch input, sensors, social, and ...
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo, June 9-11, 2015, at the Javits Center in New York City. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be
The Internet of Things is not only adding billions of sensors and billions of terabytes to the Internet. It is also forcing a fundamental change in the way we envision Information Technology. For the first time, more data is being created by devices at the edge of the Internet rather than from centralized systems. What does this mean for today's IT professional? In this Power Panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will addresses this very serious issue of profound change in the industry.
WebRTC defines no default signaling protocol, causing fragmentation between WebRTC silos. SIP and XMPP provide possibilities, but come with considerable complexity and are not designed for use in a web environment. In his session at @ThingsExpo, Matthew Hodgson, technical co-founder of the Matrix.org, discussed how Matrix is a new non-profit Open Source Project that defines both a new HTTP-based standard for VoIP & IM signaling and provides reference implementations.
Buzzword alert: Microservices and IoT at a DevOps conference? What could possibly go wrong? In this Power Panel at DevOps Summit, moderated by Jason Bloomberg, the leading expert on architecting agility for the enterprise and president of Intellyx, panelists will peel away the buzz and discuss the important architectural principles behind implementing IoT solutions for the enterprise. As remote IoT devices and sensors become increasingly intelligent, they become part of our distributed cloud environment, and we must architect and code accordingly. At the very least, you'll have no problem fil...
"People are a lot more knowledgeable about APIs now. There are two types of people who work with APIs - IT people who want to use APIs for something internal and the product managers who want to do something outside APIs for people to connect to them," explained Roberto Medrano, Executive Vice President at SOA Software, in this SYS-CON.tv interview at Cloud Expo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
Almost everyone sees the potential of Internet of Things but how can businesses truly unlock that potential. The key will be in the ability to discover business insight in the midst of an ocean of Big Data generated from billions of embedded devices via Systems of Discover. Businesses will also need to ensure that they can sustain that insight by leveraging the cloud for global reach, scale and elasticity.
In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect at GE, and Ibrahim Gokcen, who leads GE's advanced IoT analytics, focused on the Internet of Things / Industrial Internet and how to make it operational for business end-users. Learn about the challenges posed by machine and sensor data and how to marry it with enterprise data. They also discussed the tips and tricks to provide the Industrial Internet as an end-user consumable service using Big Data Analytics and Industrial Cloud.
Building low-cost wearable devices can enhance the quality of our lives. In his session at Internet of @ThingsExpo, Sai Yamanoor, Embedded Software Engineer at Altschool, provided an example of putting together a small keychain within a $50 budget that educates the user about the air quality in their surroundings. He also provided examples such as building a wearable device that provides transit or recreational information. He then reviewed the resources available to build wearable devices at home including open source hardware, the raw materials required and the options available to power s...
How do APIs and IoT relate? The answer is not as simple as merely adding an API on top of a dumb device, but rather about understanding the architectural patterns for implementing an IoT fabric. There are typically two or three trends: Exposing the device to a management framework Exposing that management framework to a business centric logic Exposing that business layer and data to end users. This last trend is the IoT stack, which involves a new shift in the separation of what stuff happens, where data lives and where the interface lies. For instance, it's a mix of architectural styles ...
We certainly live in interesting technological times. And no more interesting than the current competing IoT standards for connectivity. Various standards bodies, approaches, and ecosystems are vying for mindshare and positioning for a competitive edge. It is clear that when the dust settles, we will have new protocols, evolved protocols, that will change the way we interact with devices and infrastructure. We will also have evolved web protocols, like HTTP/2, that will be changing the very core of our infrastructures. At the same time, we have old approaches made new again like micro-services...
Connected devices and the Internet of Things are getting significant momentum in 2014. In his session at Internet of @ThingsExpo, Jim Hunter, Chief Scientist & Technology Evangelist at Greenwave Systems, examined three key elements that together will drive mass adoption of the IoT before the end of 2015. The first element is the recent advent of robust open source protocols (like AllJoyn and WebRTC) that facilitate M2M communication. The second is broad availability of flexible, cost-effective storage designed to handle the massive surge in back-end data in a world where timely analytics is e...
Collecting data in the field and configuring multitudes of unique devices is a time-consuming, labor-intensive process that can stretch IT resources. Horan & Bird [H&B], Australia’s fifth-largest Solar Panel Installer, wanted to automate sensor data collection and monitoring from its solar panels and integrate the data with its business and marketing systems. After data was collected and structured, two major areas needed to be addressed: improving developer workflows and extending access to a business application to multiple users (multi-tenancy). Docker, a container technology, was used to ...
The true value of the Internet of Things (IoT) lies not just in the data, but through the services that protect the data, perform the analysis and present findings in a usable way. With many IoT elements rooted in traditional IT components, Big Data and IoT isn’t just a play for enterprise. In fact, the IoT presents SMBs with the prospect of launching entirely new activities and exploring innovative areas. CompTIA research identifies several areas where IoT is expected to have the greatest impact.